pd-l1 biomarker status: to test or not to test? (introduction)
Published 8 years ago • 44 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
5:41
pd-l1 biomarker status: to test or not to test? (part 1)
-
0:53
pd-l1 biomarker status: to test or not to test? (conclusion)
-
6:17
pd-l1 biomarker status: to test or not to test? (part 2)
-
5:50
how is biomarker testing carried out?
-
4:47
pd-l1 biomarker testing
-
4:27
understanding immunotherapy for nsclc with pd-1 and pd-l1 biomarkers
-
18:58
pd-l1 testing by immunohistochemistry
-
10:49
is pd-l1 really a predictive biomarker?
-
1:02:49
pd-l1/pd-1 cancer immunotherapy and new targets - gordon freeman, phd
-
12:12
immune checkpoint proteins
-
46:29
biomarkers in cancer immunotherapy: what patients need to know
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
1:06
pd-l1: an important, but imperfect biomarker
-
6:14
understanding biomarker testing in non-small cell lung cancer
-
3:29
pd-l1 status: what is the current role?
-
2:27
do you order pd-l1 testing before choosing an immune checkpoint inhibitor?
-
9:54
is the pd-l1 biomarker ready for prime time?
-
4:15
pathologists and pd-l1
-
1:02
david gandara, md, current thinking regarding testing for pd-l1 biomarker in nsclc patients
-
2:13
the value of pd-l1 as a biomarker beyond lung cancers
-
1:28
dr. kim on the importance of biomarker testing for lung cancer
-
1:13
guiding nsclc treatment with biomarkers